A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Determine whether dalfampridine (Ampyra) can improve visual function in patients who have had nonarteritic ischemic optic neuropathy (NAION) with stable visual impairment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Neuro-Ophthalmologic Associates, PC
• Collaborator: Acorda Therapeutics
• Treatments: 4-Aminopyridine

Criteria

Inclusion Criteria:

• NAION 6 months prior to enrollment

• visual acuity of 20/40 or worse

Exclusion Criteria:

Current use of Dalfampridine (Ampyra)

• Pregnancy

• History of seizures

• Renal Failure

• Not able to perform testing